Diagnostic performance of p16/Ki-67 dual immunostaining at different number of positive cells in cervical smears in women referred for colposcopy

1Maver PJ, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect 2020; 26: 579-5. 83. doi: 10.1016/j.cmi.2019.09.006Maver PJ Poljak M Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans Clin Microbiol Infect 2020 26 579 5 83 10.1016/j.cmi.2019.09.00631539637Open DOISearch in Google Scholar

2Killeen JL, Dye T, Grace C, Hiraoka M. Improved abnormal Pap smear triage using cervical cancer biomarkers. J Low Genit Tract Dis 2014; 18: 1-7. doi: 10.1097/LGT.0b013e31828aeb39Killeen JL Dye T Grace C Hiraoka M Improved abnormal Pap smear triage using cervical cancer biomarkers J Low Genit Tract Dis 2014 18 1 7 10.1097/LGT.0b013e31828aeb3923760145Open DOISearch in Google Scholar

3Zhu Y, Ren C, Yang L, Zhang X, Liu L, Wang Z. Performance of p16/Ki-67 immunostaining, HPV E6/E7 mRNA testing, and HPV DNA assay to detect high-grade cervical dysplasia in women with ASCUS. BMC Cancer 2019; 19: 271. doi: 10.1186/s12885-019-5492-9Zhu Y Ren C Yang L Zhang X Liu L Wang Z Performance of p16/Ki-67 immunostaining, HPV E6/E7 mRNA testing, and HPV DNA assay to detect high-grade cervical dysplasia in women with ASCUS BMC Cancer 2019 19 271 10.1186/s12885-019-5492-9643795930917784Open DOISearch in Google Scholar

4Sawaya GF, Smith-McCune K, Kuppermann M. Cervical cancer screening: more choices in 2019. JAMA 2019; 321: 2018-9. doi: 10.1001/jama.2019.4595Sawaya GF Smith-McCune K Kuppermann M Cervical cancer screening: more choices in 2019 JAMA 2019 321 2018 9 10.1001/jama.2019.4595665635831135834Open DOISearch in Google Scholar

5White CM, Bakhiet S, Bates M, Ruttle C, Pilkington LJ, Keegan H, et al. CERVIVA consortium. Exposure to tobacco smoke measured by urinary nicotine metabolites increases risk of p16/Ki-67 co-expression and high-grade cervical neoplasia in HPV positive women: A two year prospective study. Cancer Epidemiol 2020; 68: 101793. doi: 10.1016/j.canep.2020.101793White CM Bakhiet S Bates M Ruttle C Pilkington LJ Keegan H et al CERVIVA consortium Exposure to tobacco smoke measured by urinary nicotine metabolites increases risk of p16/Ki-67 co-expression and high-grade cervical neoplasia in HPV positive women: A two year prospective study. Cancer Epidemiol 2020 68 101793 10.1016/j.canep.2020.10179332841926Open DOISearch in Google Scholar

6Gavrić Lovrec V, Erlah T, Dobnik S, Takač I. The influence of smoking on the frequency and characteristics of complications following large loop excision of the transformation zone (LLETZ). Acta medico-biotechnica 2019; 1: 40-6.Gavrić Lovrec V Erlah T Dobnik S Takač I The influence of smoking on the frequency and characteristics of complications following large loop excision of the transformation zone (LLETZ) Acta medico-biotechnica 2019 1 40 6Search in Google Scholar

7Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30(Suppl): F88-99. doi: 10.1016/j.vaccine.2012.06.095. Erratum in: Vaccine 2013; 31: 6266. doi: 10.1016/j.vaccine.2012.06.095Arbyn M Ronco G Anttila A Meijer CJ Poljak M Ogilvie G et al Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer Vaccine 2012 30 Suppl F88 99 10.1016/j.vaccine.2012.06.095 Erratum in: Vaccine 2013; 31: 6266 10.1016/j.vaccine.2012.06.09523199969Open DOISearch in Google Scholar

8Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Lüthge A, Bergeron C, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol Oncol 2011; 121: 5059. doi: 10.1016/j.ygyno.2011.02.033Petry KU Schmidt D Scherbring S Luyten A Reinecke-Lüthge A Bergeron C et al Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology Gynecol Oncol 2011 121 5059 10.1016/j.ygyno.2011.02.03321420158Open DOISearch in Google Scholar

9Wright TC Jr, Behrens CM, Ranger-Moore J, Rehm S, Sharma A, Stoler MH, et al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial. Gynecol Oncol 2017; 144: 51-6. doi: 10.1016/j.ygynoWright TC Jr Behrens CM Ranger-Moore J Rehm S Sharma A Stoler MH et al Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial Gynecol Oncol 2017 144 51 6 10.1016/j.ygynoOpen DOISearch in Google Scholar

10Schmidt D, Bergeron C, Denton KJ, Ridder R; European CINtec Cytology Study Group. p16/Ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol 2011; 119: 158-66. doi: 10.1002/cncy.20140Schmidt D Bergeron C Denton KJ Ridder R European CINtec Cytology Study Group p16/Ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study Cancer Cytopathol 2011 119 158 66 10.1002/cncy.2014021442767Open DOISearch in Google Scholar

11Bergeron C, Ikenberg H, Sideri M, Denton K, Bogers J, Schmidt D, et al. PALMS Study Group. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol 2015; 123: 373-81. doi: 10.1002/cncy.21542Bergeron C Ikenberg H Sideri M Denton K Bogers J Schmidt D et al PALMS Study Group Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol 2015 123 373 81 10.1002/cncy.2154225891096Open DOISearch in Google Scholar

12Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, et al.; PALMS Study Group. Screening for cervical cancer precursors with p16/ Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013; 105: 1550-7. doi: 10.1093/jnci/djt235Ikenberg H Bergeron C Schmidt D Griesser H Alameda F Angeloni C et al PALMS Study Group. Screening for cervical cancer precursors with p16/ Ki-67 dual-stained cytology: results of the PALMS study J Natl Cancer Inst 2013 105 1550 7 10.1093/jnci/djt235Open DOISearch in Google Scholar

13Tjalma WAA. Diagnostic performance of dual-staining cytology for cervical cancer screening: a systematic literature review. Eur J Obstet Gynecol Reprod Biol 2017; 210: 275-80. doi: 10.1016/j.ejogrbTjalma WAA Diagnostic performance of dual-staining cytology for cervical cancer screening: a systematic literature review Eur J Obstet Gynecol Reprod Biol 2017 210 275 80 10.1016/j.ejogrbOpen DOISearch in Google Scholar

14Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci US A 1996; 93: 4350-4. doi: 10.1073/pnas.93.9.4350Khleif SN DeGregori J Yee CL Otterson GA Kaye FJ Nevins JR et al Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity Proc Natl Acad Sci US A 1996 93 4350 4 10.1073/pnas.93.9.4350Open DOISearch in Google Scholar

15Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers 2007; 23: 315-30. doi: 10.1155/2007/678793. doi: 10.1155/2007/678793Wentzensen N von Knebel Doeberitz M Biomarkers in cervical cancer screening Dis Markers 2007 23 315 30 10.1155/2007/678793 10.1155/2007/678793Open DOISearch in Google Scholar

16Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998; 153: 1741-8. doi: 10.1016/S0002-9440(10)65689-1Sano T Oyama T Kashiwabara K Fukuda T Nakajima T Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions Am J Pathol 1998 153 1741 8 10.1016/S0002-9440(10)65689-1Open DOISearch in Google Scholar

17Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276-84. doi: 10.1002/ijc.1174Klaes R Friedrich T Spitkovsky D Ridder R Rudy W Petry U et al Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri Int J Cancer 2001 92 276 84 10.1002/ijc.117411291057Open DOISearch in Google Scholar

18Wang HR, Li YC, Guo HQ, Yu LL, Wu Z, Yin J, et al. A cocktail of p16INK4a and Ki-67, p16INK4a and minichromosome maintenance protein 2 as triage tests for human papillomavirus primary cervical cancer screening. Oncotarget 2017; 8: 83890-9. doi: 10.18632/oncotarget.19870Wang HR Li YC Guo HQ Yu LL Wu Z Yin J et al A cocktail of p16INK4a and Ki-67, p16INK4a and minichromosome maintenance protein 2 as triage tests for human papillomavirus primary cervical cancer screening Oncotarget 2017 8 83890 9 10.18632/oncotarget.19870566356229137390Open DOISearch in Google Scholar

19Schlüter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993; 123: 513-22. doi: 10.1083/jcb.123.3.513Schlüter C Duchrow M Wohlenberg C Becker MH Key G Flad HD et al The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins J Cell Biol 1993 123 513 22 10.1083/jcb.123.3.51322001298227122Open DOISearch in Google Scholar

20Yu L, Fei L, Liu X, Pi X, Wang L, Chen S. Application of p16/Ki-67 dual-staining cytology in cervical cancers. J Cancer 2019; 10: 2654-60. doi: 10.7150/jca.32743Yu L Fei L Liu X Pi X Wang L Chen S Application of p16/Ki-67 dual-staining cytology in cervical cancers J Cancer 2019 10 2654 60 10.7150/jca.32743658492531258773Open DOISearch in Google Scholar

21Ivanus U, Jerman T, Fokter Repse A, Takac I, Prevodnik VK, Marcec M, et al. Randomised trial of HPV self-sampling among non-attenders in the Slovenian cervical screening programme ZORA: comparing three different screening approaches. Radiol Oncol 2018; 52: 399-412. doi: 10.2478/raon-2018-0036Ivanus U Jerman T Fokter Repse A Takac I Prevodnik VK Marcec M et al Randomised trial of HPV self-sampling among non-attenders in the Slovenian cervical screening programme ZORA: comparing three different screening approaches Radiol Oncol 2018 52 399 412 10.2478/raon-2018-0036628718330216191Open DOISearch in Google Scholar

22Kloboves Prevodnik V, Jerman T, Nolde N, Repše Fokter A, Jezeršek S, Pohar Marinšek Ž, et al. Interobserver variability and accuracy of p16/Ki-67 dual immunocytochemical staining on conventional cervical smears. Diagn Pathol 2019; 1: 48. doi: 10.1186/s13000-019-0821-5Kloboves Prevodnik V Jerman T Nolde N Repše Fokter A Jezeršek S Pohar Marinšek Ž et al Interobserver variability and accuracy of p16/Ki-67 dual immunocytochemical staining on conventional cervical smears Diagn Pathol 2019 1 48 10.1186/s13000-019-0821-5653369731122253Open DOISearch in Google Scholar

23Prevodnik VK, Marinsek ZP, Zalar J, Rozina H, Kotnik N, Jerman T, et al. Evaluation of the training program for p16/Ki-67 dual immunocytochemical staining interpretation for laboratory staff without experience in cervical cytology and immunocytochemistry. Radiol Oncol 2020; 2: 201-8. doi: 10.2478/raon-2020-0018Prevodnik VK Marinsek ZP Zalar J Rozina H Kotnik N Jerman T et al Evaluation of the training program for p16/Ki-67 dual immunocytochemical staining interpretation for laboratory staff without experience in cervical cytology and immunocytochemistry Radiol Oncol 2020 2 201 8 10.2478/raon-2020-0018727664632229681Open DOISearch in Google Scholar

24Guidelines for management of women with cervical precancerous lesions. Ursic-Vrscaj M, Rakar S, Možina A, Kobal B, Takač I, Deisinger I, et al, editors. [Slovenian]. Ljubljana: Institute of Oncology Ljubljana; 2011. [Accessed 2021 Feb 5]. Available at: https://zora.onko-i.si/fileadmin/user_upload/dokumenti/strokovna_priporocila/2011_Smernice_web.pdfGuidelines for management of women with cervical precancerous lesions. Ursic-Vrscaj M, Rakar S, Možina A, Kobal B, Takač I, Deisinger I, et al, editors. [Slovenian] Ljubljana Institute of Oncology Ljubljana; 2011 [Accessed 2021 Feb 5]. Available at https://zora.onko-i.si/fileadmin/user_upload/dokumenti/strokovna_priporocila/2011_Smernice_web.pdfSearch in Google Scholar

25Waldstrøm M, Christensen RK, Ørnskov D. Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion. Cancer Cytopathol 2013; 121: 136-45. doi: 10.1002/cncy.21233Waldstrøm M Christensen RK Ørnskov D Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion Cancer Cytopathol 2013 121 136 45 10.1002/cncy.2123322987560Open DOISearch in Google Scholar

26Wentzensen N, Schwartz L, Zuna RE, Smith K, Mathews C, Gold M A, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res 2012; 18: 4154-62. doi: 10.1158/1078-0432.CCR-12-0270Wentzensen N Schwartz L Zuna RE Smith K Mathews C Gold M A et al Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population Clin Cancer Res 2012 18 4154 62 10.1158/1078-0432.CCR-12-0270423761222675168Open DOISearch in Google Scholar

27Šekoranja D, Repše Fokter A. Triaging atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion with p16/Ki-67 dual stain. J Low Genit Tract Dis 2017; 21: 108-11. doi: 10.1097/LGT.0000000000000297Šekoranja D Repše Fokter A Triaging atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion with p16/Ki-67 dual stain J Low Genit Tract Dis 2017 21 108 11 10.1097/LGT.000000000000029728244884Open DOISearch in Google Scholar

28Peeters E, Wentzensen N, Bergeron C, Arbyn M. Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology. Cancer Cytopathol 2019; 127: 169-80. doi: 10.1002/cncy.22103Peeters E Wentzensen N Bergeron C Arbyn M Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology Cancer Cytopathol 2019 127 169 80 10.1002/cncy.2210330811902Open DOISearch in Google Scholar

29Edgerton N, Cohen C, Siddiqui MT. Evaluation of CINtec PLUS® testing as an adjunctive test in ASC-US diagnosed SurePath® preparations. Diagn Cytopathol 2013; 41: 35-40. doi: 10.1002/dc.21757Edgerton N Cohen C Siddiqui MT Evaluation of CINtec PLUS® testing as an adjunctive test in ASC-US diagnosed SurePath® preparations Diagn Cytopathol 2013 41 35 40 10.1002/dc.2175721710645Open DOISearch in Google Scholar

30Dovnik A, Repše Fokter A. p16/Ki-67 Immunostaining in the triage of post-menopausal women with low-grade cytology results. J Low Genit Tract Dis 2020; 24: 235-7. doi: 10.1097/LGT.0000000000000539Dovnik A Repše Fokter A p16/Ki-67 Immunostaining in the triage of post-menopausal women with low-grade cytology results J Low Genit Tract Dis 2020 24 235 7 10.1097/LGT.000000000000053932574476Open DOISearch in Google Scholar

31Dovnik A, Repše-Fokter A. p16/Ki-67 immunostaining in the triage of young women with LSIL, ASC-US, and ASC-H cytology. Diagn Cytopathol 2020; 48: 96-7. doi: 10.1002/dc.24339Dovnik A Repše-Fokter A p16/Ki-67 immunostaining in the triage of young women with LSIL, ASC-US, and ASC-H cytology Diagn Cytopathol 2020 48 96 7 10.1002/dc.2433931714671Open DOISearch in Google Scholar

32Frega A, Pavone M, Sesti F, Leone C, Bianchi P, Cozza G, et al. Sensitivity and specificity values of high-risk HPV DNA, p16/Ki-67 and HPV mRNA in young women with atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL). Eur Rev Med Pharmacol Sci 2019; 24: 10672-7. doi: 10.26355/eurrev-201912-19765Frega A Pavone M Sesti F Leone C Bianchi P Cozza G et al Sensitivity and specificity values of high-risk HPV DNA, p16/Ki-67 and HPV mRNA in young women with atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL) Eur Rev Med Pharmacol Sci 2019 24 10672 7 10.26355/eurrev-201912-19765Open DOISearch in Google Scholar

33Wentzensen N, Clarke MA, Bremer R, Poitras N, Tokugawa D, Goldhoff PE, et al. Clinical evaluation of human papillomavirus screening with p16/Ki-67 dual stain tri-age in a large organized cervical cancer screening program. JAMA Intern Med 2019; 179: 881-8. doi: 10.1001/jamainternmed.2019.0306Wentzensen N Clarke MA Bremer R Poitras N Tokugawa D Goldhoff PE et al Clinical evaluation of human papillomavirus screening with p16/Ki-67 dual stain tri-age in a large organized cervical cancer screening program JAMA Intern Med 2019 179 881 8 10.1001/jamainternmed.2019.0306651557231081870Open DOISearch in Google Scholar

34Stoler MH, Baker E, Boyle S, Aslam S, Ridder R, Huh WK, et al. Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA. Jr. Int J Cancer 2020; 146: 599-607. doi: 10.1002/ijc.32669Stoler MH Baker E Boyle S Aslam S Ridder R Huh WK et al Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA Jr. Int J Cancer 2020 146 599 607 10.1002/ijc.32669707893931490545Open DOISearch in Google Scholar

35Giorgi Rossi P, Carozzi F, Ronco G, Allia E, Bisanzi S, Gillio-Tos A, et al. the New Technology for Cervical Cancer 2 Working Group. p16/Ki-67 and E6/E7 mRNA accuracy and prognostic value in triaging HPV DNA-positive women. J Natl Cancer Inst. 2021; 3: 292-300. doi: 10.1093/jnci/djaa105Giorgi Rossi P Carozzi F Ronco G Allia E Bisanzi S Gillio-Tos A et al the New Technology for Cervical Cancer 2 Working Group p16/Ki-67 and E6/E7 mRNA accuracy and prognostic value in triaging HPV DNA-positive women. J Natl Cancer Inst 2021 3 292 300 10.1093/jnci/djaa105793605432745170Open DOISearch in Google Scholar

36Han Q, Guo H, Geng L, Wang Y. p16/Ki-67 dual-stained cytology used for triage in cervical cancer opportunistic screening. Chin J Cancer Res 2020; 2: 208-17. doi: 10.21147/j.issn.1000-9604.2020.02.08Han Q Guo H Geng L Wang Y p16/Ki-67 dual-stained cytology used for triage in cervical cancer opportunistic screening Chin J Cancer Res 2020 2 208 17 10.21147/j.issn.1000-9604.2020.02.08721909532410798Open DOISearch in Google Scholar

37Luttmer R, Dijkstra MG, Snijders PJF, Berkhof J, van Kemenade FJ, Rozendaal L, et al. p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. Mod Pathol 2016; 29: 870-8. doi: 10.1038/modpathol.2016.80Luttmer R Dijkstra MG Snijders PJF Berkhof J van Kemenade FJ Rozendaal L et al p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population Mod Pathol 2016 29 870 8 10.1038/modpathol.2016.8027150161Open DOISearch in Google Scholar

38Ziemke P. p16/Ki-67 Immunocytochemistry in gynecological cytology: limitations in practice. Acta Cytologica 2017; 61: 230-6. doi: 10.1159/000475979Ziemke P p16/Ki-67 Immunocytochemistry in gynecological cytology: limitations in practice Acta Cytologica 2017 61 230 6 10.1159/00047597928521315Open DOISearch in Google Scholar

39Clarke MA, Cheung LC, Castle PE, Schiffman M, Tokugawa D, Poitras N, et al. Five-year risk of cervical precancer following p16/Ki-67 dual-stain triage of HPV-positive women. JAMA Oncol 2019; 5: 181-6. doi:10.1001/jamaoncol.2018.4270Clarke MA Cheung LC Castle PE Schiffman M Tokugawa D Poitras N et al Five-year risk of cervical precancer following p16/Ki-67 dual-stain triage of HPV-positive women JAMA Oncol 2019 5 181 6 10.1001/jamaoncol.2018.4270643955630325982Open DOISearch in Google Scholar

40Uijterwaal MH, Polman NJ, Witte BI, van Kemenade FJ, Rijkaart D, Berkhof J, et al. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data. J Cancer 2015; 136: 2361-8. doi: 10.1002/ijc.29290Uijterwaal MH Polman NJ Witte BI van Kemenade FJ Rijkaart D Berkhof J et al Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data J Cancer 2015 136 2361 8 10.1002/ijc.2929025345358Open DOISearch in Google Scholar